Furthermore, suppressing lipid-associated ROS production in neutrophils by LPX-1 treatment in MRL/lpr mice effectively attenuated disease progression, decreased production of autoantibodies and various inflammatory cytokines, increased serum C3 complement levels, and reduced the severity of splenomegaly, lymphadenopathy, and lupus nephritis. The gene discussed is C3; the disease is Splenomegaly.